Introduction
============

Transplantation is now recognized as the best option for treating a variety of diseases that lead to organ failure. The success of allogeneic transplantation has depended on the long-term use of non-specific immunosuppressive agents, which expose the recipient to a number of deleterious side effects, including infection and cancer. In order to facilitate the application of potentially tolerogenic therapies into clinical practice it would be helpful to identify and measure appropriate biomarkers predicting tolerance and graft acceptance. This would allow the identification of those individuals where tolerance has been established so enabling the safe reduction or withdrawal of immunosuppressive agents.

Transplantation tolerance can now be readily induced in a number of different rodent models, and it is becoming clear that such tolerance depends on the generation and activity of regulatory T cells (Treg; Qin et al., [@B22]; Cobbold et al., [@B7]). A number of different Treg populations have been described, and although we do not fully understand how they act, there seem to be a core set of genes whose expression is associated with regulation (Cobbold et al., [@B11]). The expression of many of these core genes seem to be linked to foxp3 expression (Sadlon et al., [@B24]), the "master" transcription factor for both natural and induced Treg, and therefore assays for these gene transcripts or products would seem to be primary candidates as biomarkers of tolerance. A secondary source of tolerance biomarkers might be those associated with the downstream action of Treg during maintenance of the tolerance state. The mechanisms by which Treg function *in vivo* are still unclear (Sakaguchi et al., [@B25]), but there is an emerging consensus that they act, at least in part, by modulating antigen presenting cells (APCs) from a pro-inflammatory to an anti-inflammatory or pro-tolerogenic state (Chen, [@B5]; Cobbold et al., [@B9]). Relevant APCs in this context may include not only the dendritic cells, but also other MHC-II^+^ cells in the graft such as macrophages and endothelial cells. Changes in the expression of a number of gene products have been associated with pro-tolerogenic antigen presentation, such as a relative increase in negative costimulation (e.g., PDL1; Guleria et al., [@B17]), and increased enzymatic degradation of essential amino acids (e.g., by IDO and arginase; Cobbold et al., [@B6]).

Although Treg seem to be essential to induce and maintain the tolerant state *in vivo*, we cannot assume that tolerance and activation/rejection behave as a binary switch between two alternative states. Tolerance is not just the lack of lymphocyte activation or of inflammation, as these can be achieved by immunosuppressive agents that fail to tolerize. Consequently, biomarkers reflecting a lack of inflammation may not be relevant to tolerance in the presence of immunosuppressive agents. Treg also seem to operate during any normal immune response, including the termination phase, and their presence alone is not sufficient to predict the development of tolerance. Indeed, many studies have shown that biomarkers for Treg (such as foxp3) often correlate with increasing inflammation and graft rejection rather than tolerance (Bunnag et al., [@B4]; Dijke et al., [@B13]; Huang et al., [@B20]), suggesting that Treg may play a physiological role in containing inflammation during an ongoing immune response. This suggests that the use of any Treg-based biomarker for tolerance may well depend on qualitative and contextual assessments, such as identifying an increased ratio of regulatory to inflammatory components in the context of a overall reduction in T cell and APC infiltration.

Preferred biomarkers would those that can be measured in readily accessible sources, such as blood or urine. There is accumulating evidence, however, that tolerance frequently depends on the activity of regulatory T cells locally within the target organ (Graca et al., [@B16]), and may not necessarily be associated with a systemic hyporesponsiveness to donor antigen (Cobbold et al., [@B10]). Although it may be possible to detect systemic secreted or excreted products associated with regulation (e.g., cytokines or amino acid metabolites), assays that depend on detecting Treg associated gene transcripts or cell associated products might require the use of tissue biopsies.

In this paper we investigated whether previously identified Treg and modulated APC associated gene transcripts could be used as biomarkers predicting tolerance in three different well characterized mouse skin grafting models. We found significant differences in gene expression within grafts such that we could distinguish allogeneic skin that was destined for tolerance rather than rejection, but we observed no such differences when we examined the spleen or draining lymph nodes of these recipients. Grafts destined for tolerance appeared very similar in their pattern of gene expression when compared to syngeneic grafts with both showing a reduced level of T cell and APC infiltration compared to rejecting grafts and a relative increase of Treg and modulated APC associated gene transcripts when compared to ungrafted, normal tail skin. These data suggest that the mechanisms that maintain allograft tolerance may be very similar to the local regulatory mechanisms acting to maintain self tolerance in the face of an inflammatory stimulus. This also means that there may be no unique gene signature able to form the basis of a reliable positive biomarker for transplantation tolerance.

Materials and Methods
=====================

Mice, skin grafting, and tolerance induction
--------------------------------------------

CBA/Ca, CBA.RAG1^−/−^, A1.RAG1^−/−^, B10.BR (all H-2^k^), C57BL/6 (H-2^b^) mice, were bred and maintained under SPF conditions in the animal facility of the Sir William Dunn School of Pathology, Oxford, UK. All procedures were conducted in accordance with the Home Office Animals (Scientific Procedures) Act of 1986. Tail skin was grafted on the lateral thoracic flank of recipient mice as previously described (Qin et al., [@B23]). Recipients in the tolerant groups were given 3 × 1 mg each, on days −1, +1, and +3 relative to their first grafts, of non-depleting monoclonal antibodies (Figure [1](#F1){ref-type="fig"}). A1.RAG1^−/−^ recipients were given CD4 (clone YTS 177.9.6) antibody alone (Cobbold et al., [@B10]), B10.BR grafted CBA/Ca recipients were given the CD4 plus CD8 (clone YTS 105.18.10) antibodies (Qin et al., [@B23]), and CBA/Ca recipients of C57BL/6 skin were given a cocktail of CD4 plus CD8 plus CD154 (CD40L; clone MR1) antibodies (Daley et al., [@B12]). Control recipients received either allogeneic or syngeneic tail skin grafts without antibody treatment. After 100 days all recipients were given secondary challenge skin grafts from the same strain as the original donor graft on the opposite flank (without any additional antibody treatment). Recipients were sacrificed on day 6 after second grafting and their spleens, draining lymph nodes and all surviving grafts were taken for analysis by qRT-PCR.

![**Outline of the experimental skin graft models used**.](fimmu-02-00009-g001){#F1}

Quantitative real-time RT-PCR
-----------------------------

Total RNA was prepared from tissues or whole skin grafts using SV Total RNA Lysis Buffer (Promega) and DNase-I treatment. cDNA was generated using the StrataScript First Strand Synthesis System (Stratagene), using random hexamer primers. Real-time RT-PCR and analysis were performed using the ABI/PRISM 7700 sequence detector system (Applied Biosystems) and inventoried "assay on demand" Taqman^®^ gene expression assays (Table [1](#T1){ref-type="table"}) in a low density array (TLDA) format as recommended (Applied Biosystems). Relative quantities (RQ) were calculated by the ΔΔCt method. Samples that gave no detectable signal were assigned *C*~t~ = 40. Samples were separately normalized either to a house keeping gene (*hprt1*) or to genes specifically expressed in T cells (*cd3g*) or APCs (*cd74*). All statistical analyses were performed on log transformed (RQ) data, although data is presented as a normal ratio between two samples of interest. Ratios were considered statistically significant when log\[ratio + 2 × Σ(standard deviations)\] were greater than 0 (*P* \< 0.05).

###### 

**Selection of genes for assay by Taqman qRT-PCR**.

  TaqMan Assay    Gene        TaqMan Assay    Gene         TaqMan Assay    Gene              TaqMan Assay    Gene
  --------------- ----------- --------------- ------------ --------------- ----------------- --------------- -------------------
  Hs99999901_s1   18S^10^     Mm01292449_m1   Ccr10^3^     Mm00607939_s1   Actb^10^          Mm00812512_m1   Prf1
  Mm99999915_g1   Gapdh^10^   Mm00438270_m1   Ccr2^3^      Mm00446968_m1   Hprt1^10^         Mm00442834_m1   Gzmb^7^
  Mm00434371_m1   Itga2^1^    Mm01216172_m1   Ccr3^3^      Mm00439103_m1   Gpr83             Mm00651853_m1   Stfa3^7^
  Mm00442890_m1   Itga3^1^    Mm00438271_m1   Ccr4^3^      Mm00727638_s1   Hig2              Mm00440646_m1   Furin^7^
  Mm00439770_m1   Itga4^1^    Mm01216171_m1   Ccr5^3^      Mm00441911_m1   Cd40lg            Mm00439191_m1   Gzma^7^
  Mm00439797_m1   Itga5^1^    Mm99999114_s1   Ccr6^3^      Mm00497237_m1   Icosl             Mm00516884_m1   Hp^7^
  Mm00434375_m1   Itga6^1^    Mm01301785_m1   Ccr7^3^      Mm00516023_m1   Icam1             Mm00656886_g1   Mcpt1^5,7^
  Mm00801807_m1   Itgal^1^    Mm99999115_s1   Ccr8^3^      Mm00456990_m1   Tln1              Mm00487638_m1   Cma1 (Mcpt5)^5,7^
  Mm00442916_m1   Itgb7^1^    Mm02528165_s1   Ccr9^3^      Mm00802831_m1   Igf1r             Mm00469310_m1   Ela2^7^
  Mm00441291_m1   Sell^1^     Mm99999054_s1   Cxcr3^3^     Mm00803629_m1   Phb;Fyb           Mm00435860_m1   Serpine1^7^
  Mm01204601_m1   Selplg^1^   Mm01292123_m1   Cxcr4^3^     Mm00448831_s1   Sod3              Mm00438094_g1   Cd14^8^
  Mm00497118_m1   Aass^2^     Mm00432086_m1   Cxcr5^3^     Mm00516004_m1   Hmox1             Mm00442346_m1   Tlr2^8^
  Mm00475988_m1   Arg1^2^     Mm00472858_m1   Cxcr6^3^     Mm00847448_s1   Rap1a             Mm00546288_s1   Tlr5^8^
  Mm00477592_m1   Arg2^2^     Mm00442206_s1   Xcr1^3^      Mm00487448_s1   Fut4              Mm00446193_m1   Tlr9^8^
  Mm00500289_m1   Bcat1^2^    Mm00432102_m1   Bmp7^4^      Mm01330673_g1   Fut7              Mm01291777_m1   Ahr^9^
  Mm00802192_m1   Bcat2^2^    Mm00801778_m1   Ifng^4^      Mm00449152_m1   Tyrobp            Mm00438095_m1   Cd3g^9,10^
  Mm00473573_m1   Cdo1^2^     Mm00439616_m1   Il10^4^      Mm00438867_m1   Fcer1a^5^         Mm00658576_m1   Cd74^9,10^
  Mm00516688_m1   Ddc^2^      Mm00434169_m1   Il12a^4^     Mm00445212_m1   Kit^5^            Mm00649916_m1   Ms4a4b^9^
  Mm00456709_m1   Hal^2^      Mm00439619_m1   Il17a^4^     Mm00451600_g1   Pth^5^            Mm00459296_m1   Ms4a6c^9^
  Mm00456104_m1   Hdc^2^      Mm00434228_m1   Il1b^4^      Mm00432631_m1   Cort              Mm00508099_m1   Tmem176b^9^
  Mm00515786_m1   Il4i1^2^    Mm00446185_m1   Il1rn^4^     Mm00480990_m1   Rnf128 (Grail)    Mm00463324_g1   Pilra^9^
  Mm00492586_m1   Indo^2^     Mm99999222_m1   Il2^4^       Mm00802100_m1   Alox5ap           Mm00652421_m1   Pilrb1^9^
  Mm00524206_m1   Indol1^2^   Mm00444241_m1   Il22^4^      Mm00469161_m1   Hebp1             Mm00655955_gH   Pira6^9^
  Mm00500918_m1   Pah^2^      Mm00518984_m1   Il23a^4^     Mm01298628_m1   Skap1             Mm00776306_mH   Klra6^9^
  Mm00451856_g1   Tdh^2^      Mm00445259_m1   Il4^4^       Mm00493634_m1   Tgfbi             Mm00452054_m1   Cd274^9^
  Mm00451266_m1   Tdo2^2^     Mm00439646_m1   Il5^4^       Mm00457979_m1   Zbp1              Mm00435532_m1   Pdcd1^9^
  Mm00546816_m1   Tha1^2^     Mm00446190_m1   Il6^4^       Mm00656724_m1   Egr1^6^           Mm00711660_m1   Cd80^9^
  Mm00493794_m1   Tph1^2^     Mm00434305_m1   Il9^4^       Mm00456650_m1   Egr2^6^           Mm00444543_m1   Cd86^9^
  Mm00440485_m1   Nos2^2^     Mm00441724_m1   Tgfb1^4^     Mm00475164_m1   Foxp3^6^          Mm00486849_m1   Ctla4^9^
  Mm00522563_m1   Mat1a^2^    Mm00436952_m1   Tgfb2^4^     Mm00484683_m1   Gata3^6^          Mm00514644_m1   S1pr1^9^
  Mm00506137_m1   Mat2b^2^    Mm00434189_m1   Il12rb1^4^   Mm00515191_m1   Irf1^6^           Mm00488795_m1   Clec4a^2^
  Mm00444228_m1   Ccl20^3^    Mm00434200_m1   Il12rb2^4^   Mm00516431_m1   Irf4^6^           Mm00490931_m1   Clec4n
  Mm00436446_g1   Ccl6^3^     Mm00434223_m1   Il17ra^4^    Mm03682796_m1   Rorc^6^           Mm00496572_m1   Gp49a
  Mm00436450_m1   Cxcl2^3^    Mm00439622_m1   Il1r2^4^     Mm00443103_m1   Rora^6^           Mm00656925_m1   S100a9
  Mm00469294_m1   Ebi3^3^     Mm00519942_m1   Il23r^4^     Mm00450960_m1   Tbx21^6^          Mm00802901_m1   Lgals3
  Mm01216147_m1   Ccr1^3^     Mm01212875_m1   Penk         Mm00491292_g1   Zbtb32^6^ (ROG)   Mm00436767_m1   Spp1

*^1^Adhesion molecule, ^2^Amino acid metabolism, ^3^Chemokine/chemokine receptor, ^4^Cytokine/cytokine receptor, ^5^Mast cells, ^6^Transcription factor, ^7^Protease/proteolysis, ^8^Receptor/immunity/defense, ^9^Signal transduction/immunity defence, ^10^Normalizing controls*.

Selection of markers for T cells and APCs as indicators of immune responses
---------------------------------------------------------------------------

The Taqman qRT-PCR gene transcript assays that were chosen for analysis are shown in (Table [1](#T1){ref-type="table"}). They were selected on the basis of the following criteria: "signature genes" which were mainly those considered a "master" transcription factors or cytokines for functionally relevant T cell subsets (Th1, Th2, Tr1, Th17, and Treg); chemokine receptors and adhesion molecules likely to be important in any differential trafficking or accumulation of T cell or APC subsets in grafts or lymph nodes; enzymes implicated in the consumption of essential amino acids by APCs under regulatory conditions, mast cell genes (as mast cells have been previously implicated in tolerance; Lu et al., [@B21]) and additional genes we had previously shown to be associated with either regulatory T cells or modulated dendritic cells by serial analysis of gene expression (Cobbold et al., [@B11]).

Results
=======

Mouse models of tolerance
-------------------------

We chose models where the only source of donor antigen was the skin graft itself, as we have already shown that these models depend on the continued presence of Treg within the graft for the maintenance of the tolerance state (Graca et al., [@B16]; Cobbold et al., [@B7]). Such tolerance is defined by the ability to accept fresh donor-type skin grafts even though normal, but systemic T cell reactivity to donor antigen generally appears to remain intact when assayed *in vitro* (Cobbold et al., [@B8]), so that conventional *in vitro* tests have not provided any useful biomarkers in such models. All three models used the same fully tolerance permissive CBA/Ca gene background recipients, but varied in the frequency of donor antigen specific T cells from 100% (A1.RAG transgenic recipients given syngeneic male skin and non-depleting CD4 antibody) to ∼1% (CBA/Ca recipients given MHC and minor mismatched C567BL/6 skin and both CD4, CD8, and CD40L antibodies) to \<\<0.1% (CBA/Ca recipients given multiple minor mismatched B10.BR skin and CD4 plus CD8 antibodies; Figure [1](#F1){ref-type="fig"}). In order to compare intact grafts (on day 6 after grafting) that we knew were destined to be accepted or rejected we focused on an analysis of secondary challenge grafts in recipients that had been previously tolerized by grafting and antibody co-administration or that had been primed by prior skin grafting alone. We also included a group of recipients given only syngeneic primary and secondary skin grafts so that we could potentially distinguish antigen specific and non-antigen specific components of any response. We also analyzed spleen and draining lymph nodes from all these mice at the same time.

Limitations of Foxp3 as a potential biomarker of tolerance
----------------------------------------------------------

We first analyzed the differential expression of the "master" Treg gene Foxp3 (Hori et al., [@B19]). No significant differences in foxp3 between tolerant and rejecting recipients were observed in any of the three models in the spleen or draining lymph nodes. Total Foxp3 (when normalized to house keeping gene *hprt1*; Table [2](#T2){ref-type="table"}) was unable to distinguish between any of the challenge grafts destined for tolerance compared to those primed for rejection (Table [2](#T2){ref-type="table"}). When Foxp3 values were normalized to the level of T cell infiltration, as indicated by CD3γ expression, there was some indication that a higher proportion of T cells expressed the Treg associated gene in the two models with the higher frequency of donor specific T cells, but there was still a high degree of variation between different individuals in the TCR transgenic group at this time point, particularly in the CD3γ content, which therefore failed to reach statistical significance. If such individual variation, either between individuals or over time, of relevant transcripts were a general finding this would limit their predictive value as biomarkers. The only striking increase in Foxp3, whether normalized to *hprt1* or CD3γ, was observed when the originally long-term surviving tolerated allogeneic skin was compared with a similarly long-term accepted syngeneic graft in the TCR transgenic model where all T cells were specific for donor antigen. Therefore, Foxp3 does not seem to reliably correlate with transplantation tolerance in these models.

###### 

**Foxp3 expression in grafts is not a reliable indicator of tolerance**.

  -----------------------------------------------------------------------------------------------------------------------------
                    Comparison                    *Foxp3*/\                              *Foxp3*/\
                                                  *Hprt1* ratio                          *Cd3g* ratio
  ----------------- ----------------------------- -------------------------------------- --------------------------------------
  B10BR → CBA       Tol vs Rej challenge grafts   0.41                                   1

  (*n* = 4/group)   Tol vs Syn challenge grafts   0.76                                   1.1

                    Tol vs Syn original grafts    2.1                                    1

                                                                                         

  C57BL/6 → CBA     Tol vs Rej challenge grafts   1.6                                    3.6[\*](#tfn1){ref-type="table-fn"}

  (*n* = 4/group)   Tol vs Syn challenge grafts   0.8                                    3.2

                    Tol vs Syn original grafts    1.1                                    1

                                                                                         

  Male → A1RAG      Tol vs Rej challenge grafts   0.8                                    5.3

  (*n* = 6/group)   Tol vs Syn challenge grafts   0.6                                    0.9

                    Tol vs Syn original grafts    38.2[\*](#tfn1){ref-type="table-fn"}   25.5[\*](#tfn1){ref-type="table-fn"}
  -----------------------------------------------------------------------------------------------------------------------------

\**P* \< *0.05, all other ratios were non-significant*.

Other genes that potentially distinguish tolerant and rejecting skin
--------------------------------------------------------------------

We performed similar comparisons between challenge grafts given to tolerant and primed recipients for a set of more than 150 genes representative of the following categories: amino acid metabolism, signature T cell subset transcription factors, signature cytokines, chemokine receptors, adhesion molecules, mast cell genes, and additional genes associated with regulatory T cell subsets or modulated APCs previously identified by serial analysis of gene expression (Table [1](#T1){ref-type="table"}). Surprisingly, none of the genes tested were found to differ significantly between tolerant, rejecting or syngeneic grafted recipients when samples from the spleen or draining lymph node were compared, which strongly supports the hypothesis (Cobbold et al., [@B7]) that tolerance and immune regulation act primarily within the local grafted tissue in these models. We did find in all three models that rejecting grafts tended to exhibit higher levels, when compared to tolerated grafts, of both CD3γ and CD74 gene transcripts, when normalized to a house keeping gene such as hprt1 (Table [3](#T3){ref-type="table"}), suggesting an increased infiltration of T cells and APC in grafts destined for rejection. In the MHC mismatched model, where CD3γ and CD74 were most significantly associated with rejection (Table [4](#T4){ref-type="table"}), the additional genes upregulated in rejecting grafts included Th1 related genes such as *Ifng* and *Gzmb*, the Th2 related *Il4* and Th17 inducing *Il6*. Some genes usually associated with regulation were also over-expressed in rejecting grafts, including *Indo*, *Nos2*, *Arg1*, *Indol1*, and *foxp3* (as discussed earlier). Note that none of these differences were observed in the draining lymph nodes.

###### 

**Infiltration of skin grafts by T cells and APCs**.

  ----------------------------------------------------------------------------------------------------------------------------
                    Comparison                    *CD3g*/\                               *CD74*/\
                                                  *Hprt1* ratio                          *Hprt1* ratio
  ----------------- ----------------------------- -------------------------------------- -------------------------------------
  B10BR → CBA       Rej vs Tol challenge grafts   6.1[\*](#tfn2){ref-type="table-fn"}    3.8[\*](#tfn2){ref-type="table-fn"}

  (*n* = 4/group)   Tol vs Syn challenge grafts   1.4                                    1.2

                    Tol vs Syn original grafts    2.3                                    1

                                                                                         

  C57BL/6 → CBA     Rej vs Tol challenge grafts   16.6[\*](#tfn2){ref-type="table-fn"}   7.1[\*](#tfn2){ref-type="table-fn"}

  (*n* = 4/group)   Tol vs Syn challenge grafts   4.2                                    1.8

                    Tol vs Syn original grafts    1.1                                    0.9

                                                                                         

  Male → A1RAG      Rej vs Tol challenge grafts   8.3                                    2.6

  (*n* = 6/group)   Tol vs Syn challenge grafts   8.6                                    2.3

                    Tol vs Syn original grafts    1.5                                    0.2
  ----------------------------------------------------------------------------------------------------------------------------

\**P* \< *0.05, all other ratios were non-significant*.

###### 

**Genes associated with rejection in C57BL/6 → CBA (fully allogeneic) skin grafts**.

                                                                                         Gene                                    Rej:Tol 2nd graft ratio                 Rej:Tol lymph node ratio
  -------------------------------------------------------------------------------------- --------------------------------------- --------------------------------------- --------------------------
                                                                                         *Cd3g*                                  13.2[\*](#tfn3){ref-type="table-fn"}    *1.1*
                                                                                         *Cd74*                                  7.06[\*](#tfn3){ref-type="table-fn"}    *1.05*
  Genes over-expressed in rejecting compared to tolerated grafts normalized to *Hprt1*   *Indo*                                  121.0[\*](#tfn3){ref-type="table-fn"}   *0.6*
  *Nos2*                                                                                 118.0[\*](#tfn3){ref-type="table-fn"}   *1.3*                                   
  *Ifng*                                                                                 86.9[\*](#tfn3){ref-type="table-fn"}    *1.5*                                   
  *Gzmb*                                                                                 84.0[\*](#tfn3){ref-type="table-fn"}    *ND*                                    
  *Arg1*                                                                                 18.5[\*](#tfn3){ref-type="table-fn"}    *2.6*                                   
  *Il4*                                                                                  31.7[\*](#tfn3){ref-type="table-fn"}    *0.5*                                   
  *Il6*                                                                                  27.6[\*](#tfn3){ref-type="table-fn"}    *1.5*                                   
  *Indol1*                                                                               14.8[\*](#tfn3){ref-type="table-fn"}    *1.0*                                   

\**P* \< *0.05 (n* = *6/group), all other ratios were non-significant*.

*ND, not determined*.

The corollary of these data is that tolerated skin grafts tended to have a reduced infiltration by T cells and APCs as indicated by CD3γ and CD74 expression, and none of the genes tested ( normalized to house keeping genes) were positively correlated with tolerance. We therefore estimated the relative contribution of different T cell and APC differentiation pathways by normalizing T cell expressed transcripts to CD3γ and APC related transcripts to CD74. In the TCR transgenic model 5 T cell associated transcripts were found to be significantly over-expressed within tolerant compared to rejecting grafts (*Rorc*, *Gata3*, *Egr2*, *Rnf128*, and *Tgfb1*; Table [5](#T5){ref-type="table"}) when normalized to CD3γ while *Bmp7* was the only over-expressed APC related gene (normalized to MHC-II invariant chain, CD74). When we examined the C57BL/6 → CBA/Ca model we also observed over-expression of *Rorc*, *Gata3*, and *Tgfb1* in tolerated grafts (Table [6](#T6){ref-type="table"}), while *Gata3* and *Bmp7* were differential in the B10.BR-CBA model (Table [7](#T7){ref-type="table"}). Over-expression of the energy related genes *Egr2* (Harris et al., [@B18]) and *Rnf128* (Grail; Anandasabapathy et al., [@B1]) was only observed in the TCR transgenic model where there were no non-antigen specific T cells present to overwhelm the antigen specific signal. A variety of amino acid catabolizing enzymes were also relatively increased (normalized to CD74) in tolerated MHC and minors different skin grafts (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). The tolerance associated genes in common suggest a weak bias away from Th1 responses to Th17 or NK cells (*Rorc*), Th2 cells (*Gata3*), and Treg activity (*Tgfb1*), but there is little evidence of the dominant signature containing the variety of regulatory-associated genes that one might have expected. Perhaps even more surprisingly, the secondary challenge MHC mismatched skin grafts in tolerant recipients were almost indistinguishable by their patterns of gene expression to equivalent syngeneic grafts (Table [6](#T6){ref-type="table"}).

###### 

**Differential gene expression in male → female A1.RAG^−/−^ skin grafts**.

                                                                                                      Gene                                    Ratio
  --------------------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------
  T cell related genes over-expressed in tolerated compared to rejecting grafts (*Cd3g* normalized)   *Rorc*                                  23.43[\*](#tfn4){ref-type="table-fn"}
  *Gata3*                                                                                             13.85[\*](#tfn4){ref-type="table-fn"}   
  *Egr2*                                                                                              9.76[\*](#tfn4){ref-type="table-fn"}    
  *Rnf128* (grail)                                                                                    8.40[\*](#tfn4){ref-type="table-fn"}    
  *Tgfb1*                                                                                             5.93[\*](#tfn4){ref-type="table-fn"}    
  *Foxp3*                                                                                             *5.32*                                  
                                                                                                                                              
  APC related genes over-expressed in tolerated compared to rejecting grafts (*Cd74* normalized)      *Bmp7*                                  5.01[\*](#tfn4){ref-type="table-fn"}

\**P* \< *0.05* (*n* = *6/group*), *all others ratios non-significant*.

###### 

**Differential gene expression in C57BL/6 → CBA (fully allogeneic) skin grafts**.

                                                                                            Gene                                   Tol:Rej 2nd grafts ratio               Tol:Rej lymph nodes ratio   Tolerant:syngeneic 2nd grafts ratio
  ----------------------------------------------------------------------------------------- -------------------------------------- -------------------------------------- --------------------------- -------------------------------------
  T cell genes upregulated in tolerated compared to rejecting grafts normalized to *Cd3g*   *Ccl5*                                 45.9[\*](#tfn5){ref-type="table-fn"}   *ND*                        *ND*
  *Gata3*                                                                                   41.0[\*](#tfn5){ref-type="table-fn"}   *1.3*                                  *0.66*                      
  *Rora*                                                                                    40.2[\*](#tfn5){ref-type="table-fn"}   *ND*                                   *ND*                        
  *Ccl20*                                                                                   40.1[\*](#tfn5){ref-type="table-fn"}   *ND*                                   *ND*                        
  *Rorc*                                                                                    29.6[\*](#tfn5){ref-type="table-fn"}   *2.7*                                  *0.40*                      
  *Itga6*                                                                                   22.5[\*](#tfn5){ref-type="table-fn"}   *ND*                                   *ND*                        
  *Itga3*                                                                                   18.0[\*](#tfn5){ref-type="table-fn"}   *ND*                                   *ND*                        
  *Il9*                                                                                     14.6[\*](#tfn5){ref-type="table-fn"}   *1.4*                                  *1.74*                      
  *Tgfb1*                                                                                   9.4[\*](#tfn5){ref-type="table-fn"}    *1.0*                                  *0.91*                      
  *Ccr9*                                                                                    7.0[\*](#tfn5){ref-type="table-fn"}    *ND*                                   *ND*                        
  *Rap1a*                                                                                   6.7[\*](#tfn5){ref-type="table-fn"}    *ND*                                   *ND*                        
                                                                                                                                                                                                      
  APC genes upregulated in tolerated compared to rejecting grafts normalized to *Cd74*      *Tdh*                                  51.2[\*](#tfn5){ref-type="table-fn"}   *0.9*                       *1.63*
  *Ddc*                                                                                     34.8[\*](#tfn5){ref-type="table-fn"}   *0.4*                                  *2.05*                      
  *Tgfb2*                                                                                   21.9[\*](#tfn5){ref-type="table-fn"}   *1.7*                                  *0.96*                      
  *Hal*                                                                                     16.1[\*](#tfn5){ref-type="table-fn"}   *1.2*                                  *0.60*                      
  *Cdo1*                                                                                    12.5[\*](#tfn5){ref-type="table-fn"}   *2.9*                                  *1.09*                      
  *Bcat2*                                                                                   10.8[\*](#tfn5){ref-type="table-fn"}   *1.7*                                  *0.78*                      
  *Bcat1*                                                                                   7.4[\*](#tfn5){ref-type="table-fn"}    *0.8*                                  *0.67*                      

\**P* \< *0.05* (*n* = *4/group*), *all other ratios were non-significant*.

*ND, not determined*.

###### 

**Differential gene expression in B10BR → CBA (multiple minors) skin grafts**.

                                                                                                 Gene                                   Ratio
  ---------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------
  T cell genes over-expressed in tolerant compared to rejecting 2nd grafts (*Cd3g* normalized)   *Gata3*                                11.1[\*](#tfn6){ref-type="table-fn"}
  *Tgfb1*                                                                                        *4.3*                                  
                                                                                                                                        
  APC genes over-expressed in tolerant compared to rejecting 2nd grafts (*Cd74* normalized)      *Aass*                                 42.7[\*](#tfn6){ref-type="table-fn"}
  *Bmp7*                                                                                         11.2[\*](#tfn6){ref-type="table-fn"}   
  *Hal*                                                                                          6.4[\*](#tfn6){ref-type="table-fn"}    
  *Mcpt5*                                                                                        4.7[\*](#tfn6){ref-type="table-fn"}    
  *Tdh*                                                                                          *14.2*                                 

\**P* \< *0.05* (*n* = *4/group*), *all other ratios non-significant*.

This latter observation suggested two possibilities -- first, that tolerated skin grafts, once fully accepted and healed in, no longer require active regulation and are effectively ignored by the immune system, or second, that both allogeneic and syngeneic skin require similar active immune regulation to maintain their tolerant status. We have already shown, by transferring skin grafts to secondary RAG1^−/−^ recipients and subsequent depletion of Treg that tolerated grafts contain primed effector cells that are actively held in check by Treg (Cobbold et al., [@B7]), so the first possibility seems unlikely. We found there were a large number of genes upregulated early during the process of skin grafting (Table [8](#T8){ref-type="table"}), even in T cell deficient recipients, many of which may also have an immunoregulatory function \[e.g., *Bcat1*, *Hdc*, *Arg1*, *Ebi3*, *Gzma*, *Tdh*, and *Tmem176b* (TORID)\]. We then looked for additional genes expressed by long-term surviving syngeneic skin grafts on CBA/Ca recipients with an intact immune system compared with freshly harvested normal tail skin we found that the syngeneic grafts were highly enriched for Treg associated gene transcripts (Table [9](#T9){ref-type="table"}), including *Foxp3*, *Gata3*, *Il10*, and *Zbtb32* (ROG) and modulated APCs (*IL4i1* and *Nos2*). This latter result may represent an amplification of the normal bias toward regulatory T cells that has been previously described in the skin and which has been suggested to maintain (self) tolerance in the face of an inflammatory stimulus (Dudda et al., [@B15]). In other words, it is possible that self tolerance to certain skin antigens is also dependent on active regulation.

###### 

**Genes over-expressed in skin during the process of grafting and in the absence of adaptive immunity**.

  -----------------------------------------------------------------------------------------------------------------
                                      Gene                                   Ratio
  ----------------------------------- -------------------------------------- --------------------------------------
  Genes upregulated in skin during\   *Spp1*                                 83.8[\*](#tfn7){ref-type="table-fn"}
  the process of grafting in the\                                            
  absence of adaptive immunity\                                              
  (*Hprt1* normalized)                                                       

  *Bcat1*                             52.4[\*](#tfn7){ref-type="table-fn"}   

  *Il1b*                              39.3[\*](#tfn7){ref-type="table-fn"}   

  *Clec4a2*                           30.2[\*](#tfn7){ref-type="table-fn"}   

  *Ms4a6c*                            27.6[\*](#tfn7){ref-type="table-fn"}   

  *Gp49a;Lilrb4*                      20.9[\*](#tfn7){ref-type="table-fn"}   

  *Tyrobp*                            19.1[\*](#tfn7){ref-type="table-fn"}   

  *Pilra*                             18.5[\*](#tfn7){ref-type="table-fn"}   

  *Clec4n*                            17.3[\*](#tfn7){ref-type="table-fn"}   

  *Zbp1*                              13.5[\*](#tfn7){ref-type="table-fn"}   

  *Ccr1*                              12.6[\*](#tfn7){ref-type="table-fn"}   

  *Hdc*                               11.6[\*](#tfn7){ref-type="table-fn"}   

  *Cd80*                              10.8[\*](#tfn7){ref-type="table-fn"}   

  *Arg1*                              10.4[\*](#tfn7){ref-type="table-fn"}   

  *Ccr7*                              8.7[\*](#tfn7){ref-type="table-fn"}    

  *Pira6*                             8.3[\*](#tfn7){ref-type="table-fn"}    

  *Cd86*                              8.3[\*](#tfn7){ref-type="table-fn"}    

  *Ebi3*                              7.9[\*](#tfn7){ref-type="table-fn"}    

  *Hp*                                7.9[\*](#tfn7){ref-type="table-fn"}    

  *Gzma*                              6.2[\*](#tfn7){ref-type="table-fn"}    

  *Mcpt5*                             6.1[\*](#tfn7){ref-type="table-fn"}    

  *Tlr2*                              5.2[\*](#tfn7){ref-type="table-fn"}    

  *Alox5ap*                           4.9[\*](#tfn7){ref-type="table-fn"}    

  *Ms4a4b*                            4.4[\*](#tfn7){ref-type="table-fn"}    

  *Tdh*                               4.1[\*](#tfn7){ref-type="table-fn"}    

  *Tmem176b*                          4.1[\*](#tfn7){ref-type="table-fn"}    

  *Irf1*                              3.8[\*](#tfn7){ref-type="table-fn"}    

  *Ccl6*                              3.7[\*](#tfn7){ref-type="table-fn"}    

  *Hmox1*                             3.5[\*](#tfn7){ref-type="table-fn"}    

                                                                             

  *Foxp3*                             *0.5*                                  

  *Cd3g*                              0.5                                    

  *CD74*                              1.5                                    
  -----------------------------------------------------------------------------------------------------------------

\**P* \< *0.05* (*n* = *4/group*), *other ratios non-significant*.

###### 

**Syngeneic skin grafts over-express genes associated with regulatory cells**.

                                                                                                                           Gene                                   Ratio
  ------------------------------------------------------------------------------------------------------------------------ -------------------------------------- --------------------------------------
  Genes over-expressed in syngeneic original grafts vs normal skin (*Hprt1* normalized)[^+^](#tfn9){ref-type="table-fn"}   *Foxp3*                                40.1[\*](#tfn8){ref-type="table-fn"}
  *Il4i1*                                                                                                                  17.1[\*](#tfn8){ref-type="table-fn"}   
  *Zbtb32*(ROG)                                                                                                            13.0[\*](#tfn8){ref-type="table-fn"}   
  *Nos2*                                                                                                                   4.7[\*](#tfn8){ref-type="table-fn"}    
  *Il10*                                                                                                                   4.7[\*](#tfn8){ref-type="table-fn"}    
  *Gata3*                                                                                                                  3.3[\*](#tfn8){ref-type="table-fn"}    

\**P* \< *0.05* (*n* = *4/group)*.

^+^*This table excludes all genes listed in Table [8](#T8){ref-type="table"} as over-expressed in the absence of adaptive immunity*.

Discussion
==========

Although foxp3 represents the best marker currently available for identifying regulatory T cells, we found that it could not be used as a reliable biomarker to indicate transplantation tolerance even when we analyzed the grafted tissue itself. Indeed, absolute foxp3 levels were often higher in grafts undergoing rejection, as has been previously reported (Dijke et al., [@B14]; Yang et al., [@B29]; Bunnag et al., [@B4]). One reason for this might be that foxp3 can be transiently expressed in activated effector T cells (Wang et al., [@B28]). An alternative possibility is that foxp3^+^ regulatory T cells are attracted to all sites of inflammation where they act to limit immune pathology, but it is the balance of activation vs regulation that determines the eventual outcome of rejection or tolerance, respectively. One way to estimate this balance would be to normalize the foxp3 expression for the number of T cells present, but this approach was still unable to provide a clear correlation with graft outcome, suggesting that the numbers of effector and regulatory T cells within a graft may be closely coupled and finely balanced.

There are two findings from this study that suggest that it may not be possible to identify biomarkers that uniquely identify tolerance in recipients of allografts. First, the only significant differences in gene expression between tolerated, rejecting and syngenic responses were observed within the grafted organ itself, and not in draining lymph nodes or spleens. This may be due to alloantigen specific T cells preferentially accumulating at the main site of antigen, i.e., within the graft itself (Graca et al., [@B16]; Cobbold et al., [@B10]). In order to observe donor specific tolerance associated biomarkers systemically it may be necessary for the alloantigen to also be systemically distributed, as may be seen, for example, in some liver transplant recipients that develop macrochimerism (Starzl et al., [@B26]), by inducing tolerance by chronic administration of soluble peptide antigen (Apostolou and von Boehmer, [@B2]), or by providing a systemic alloantigen boost to enrich Treg in the lymphoid tissues (Bemelman et al., [@B3]). Second, the pattern of gene expression that distinguished tolerated from rejecting grafts, i.e., a reduced inflammatory infiltrate and a bias toward regulatory T cell and APC associated transcripts, was indistinguishable from that seen in syngeneic grafts (except in the TCR transgenic model where all T cells were donor antigen specific).

Although a lack of inflammation in tolerated grafts is an important observation, it may not represent a useful predictive biomarker in the context of clinical transplantation at the point where the recipients are still on high doses of immunosuppressive and anti-inflammatory drugs. The similarity between tolerated allografts and syngeneic grafts also suggests that transplantation tolerance is probably maintained by the same mechanisms that are actively maintaining self tolerance in normal peripheral tissues. While allo-tolerance is being maintained, at least in part, by an antigen specific regulatory T cell population (as observed in the monospecific TCR transgenic model), in a recipient with an intact polyclonal repertoire the frequency of allospecific regulatory cells, even within grafts, will likely be too low to provide a distinct and detectable gene signature above the background of regulation mediated by innate and self reactive components. This background response to syngeneic grafts may be very similar to the normal process of limiting an inflammatory or healing response throughout the body, so any systemically detectable tolerance associated gene products may be uninformative with respect to the state of the allograft.

A detection of systemic regulatory gene products may, however, provide some indication of whether a particular immunosuppressive regimen is permissive rather than inhibitory of immune regulatory mechanisms in general. Published biomarkers \[from "Reprogramming the Immune System for Establishment of Tolerance" (RISET) and "International Tolerance Network" (ITN) Turka et al., [@B27]\] may therefore be more indicative of the systemic responses of individual patients to immunosuppressive agents and the type of graft they received than tolerance to the graft alloantigens *per se*.

We used skin grafts throughout these experiments as these represent our most robust and well characterized model systems of donor antigen specific tolerance that is completely dependent on the presence of Tregs within the tolerated tissue (Graca et al., [@B16]; Cobbold et al., [@B7]), but it is possible that the vascularized organ grafts most often used clinically may differ from skin grafts, particularly in their initial healing and angiogenic responses. Skin grafts, however, are already re-vascularized by day 4, and we found that tolerated allografts were similar in their regulatory gene signature to syngeneic grafts at both 6 and +100 days post grafting, when any initial vascularization, wound healing and ischemic reperfusion responses would have resolved. We would therefore have no reason to expect that our findings from skin grafting would differ, in general terms, to the transplantation of vascularized organs.
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